Summary
Demethoxydaunorubicin (DMDR), a new anthracycline available both for intravenous and oral administration, was given in 14 cases of leukaemia, non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) replacing either daunorubicin (DNR) or doxorubicin (DOX) in conventional chemotherapy regimes.
In acute leukaemia (6 myeloblastic and 1 common lymphoblastic) there were 5 complete (CR) and 2 partial (PR) remissions; one patient, previously brought into remission with a regime including i. v. DMDR was thereafter maintained in CR with oral DMDR.
Among the patients treated with the oral DMDR, 2 NHL cases were treated; 1 patient had a sustained remission of 12 months so far, with DMDR alone; another patient had a CR with a combined regime. In MM, one patient with very advanced disease treated with i. v. DMDR/CHOP did not respond, but three cases treated with oral DMDR plus other drugs showed a partial remission.
Toxic effects were limited to brief episodes of nausea and vomiting in a few i. v. treated patients; a prolonged bone marrow depression was observed in one case only. No cardiotoxic effect was recorded.
This is a preview of subscription content, log in via an institution to check access.
References
Arcamone F, Bernardi L, Giardino P, Di Marco A, Casazza AM, Pratesi G (1976) Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin and their anomers. Cancer Treat Rep 60: 829
Bargiotti A, Casazza AM, Cassinelli G, Di Marco A, Penco S, Pratesi G, Supino R, Zaccara A, Zunino F, Arcamone F (1983) Synthesis, biological and biochemical properties of new anthracycline modified in the amino sugar moiety. Cancer Chemother Pharmacol 10: 84
Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase 1 and clinical pharmacological studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096
Blum RH, Carter SK (1974) Adriamycin: A new anticancer agent with significant clinical activity. Ann Intern Med 80: 242
Casazza AM (1979) Experimental evaluation of anthracycline analogues. Cancer Treat Rep 63: 835
Di Marco A, Casazza AM, Pratesi G (1977) Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61: 893
Eridani S, Pearson TC, Slater NGP, Singh AK (1984) A pilot study of Epidoxorubicin in combination treatment of acute leukaemia and non-Hodgkin lymphoma. Oncology 41: 383
Lambertenghi-Deliliers E, Pogliani E, Pacciarini MA, Polli EE (1984) Idarubicin; an anthracycline compound active in leukemia. Proc A A Can Res 25: 748
Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht P, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper RM, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SF, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukaemia Group B. Blood 58: 1203
Skarin AT, Rosenthal DS, Moloney WC, Frei E III (1977) Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). Blood 49: 759
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eridani, S., Slater, N.G.P., Singh, A.K. et al. Intravenous and oral demethoxydaunorubicin (NSC 256–439) in the treatment of acute leukemia and lymphoma: A pilot study. Blut 50, 369–372 (1985). https://doi.org/10.1007/BF00320931
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320931